Regeneron Pharmaceuticals market cap REGN
Share price times shares outstanding: what the whole company sells for, since 2010.
- Today, Nov 3, 2026
- $100B
- Highest close in our data
- $132.2B
- Aug 2024
Regeneron Pharmaceuticals is worth $100B at the close on Nov 3, 2026, at $970.82 a share.
That is up 45% over the last year and up 52% over five years.
Its highest close in our data was $132.2B in Aug 2024.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $99B | $63.9B | $99B | +20% |
| 2025 | $82.5B | $52.9B | $82.5B | +5% |
| 2024 | $78.3B | $77.1B | $132.2B | −18% |
| 2023 | $95.7B | $76B | $95.7B | +22% |
| 2022 | $78.6B | $62.8B | $83.5B | +16% |
| 2021 | $67.9B | $48.3B | $72.7B | +32% |
| 2020 | $51.6B | $37.1B | $72.5B | +26% |
| 2019 | $41B | $30B | $48B | +4% |
| 2018 | $39.2B | $31.4B | $44B | −3% |
| 2017 | $40.4B | $36.5B | $55B | +4% |
| 2016 | $38.7B | $35.7B | $51.2B | −31% |
| 2015 | $56.5B | $41.3B | $60.3B | +34% |
| 2014 | $42B | $27B | $43.5B | +53% |
| 2013 | $27.5B | $15.6B | $30.5B | +70% |
| 2012 | $16.2B | $6B | $17.5B | +223% |
| 2011 | $5B | $2.7B | $5.9B | +91% |
| 2010 | $2.6B | $1.8B | $2.7B | n/a |
Against its peers
Companies in Biotechnology nearest Regeneron Pharmaceuticals' size, closest first, today.
| Company | Market cap |
|---|---|
| REGNRegeneron Pharmaceuticals | $100B |
| VRTXVertex Pharmaceuticals | $137.1B |
| ONCBeOne Medicines | $40.2B |
| UTHRUnited Therapeutics | $25.9B |
| INCYIncyte | $24.3B |
| ALNYAlnylam Pharmaceuticals | $21.2B |
| EXELExelixis | $17.4B |
| NBIXNeurocrine Biosciences | $14.8B |
| HALOHalozyme Therapeutics | $14.6B |
| TECHBIO-TECHNE | $11.4B |
| Peer median | $21.2B |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Regeneron Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.